DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Combivent (Ipratropium Bromide / Albuterol Sulfate) - Summary

 
 



COMBIVENT SUMMARY

Combivent® Inhalation Aerosol is a combination of ipratropium bromide and albuterol sulfate.

Combivent Inhalation Aerosol is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.


See all Combivent indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Combivent (Ipratropium / Albuterol)

COPD (Chronic Obstructive Pulmonary Disease)
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2014.03.18]
Title: COPD (Chronic Obstructive Pulmonary Disease)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/18/2014 7:18:35 PM

COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.20]
Title: COPD Foods Pictures Slideshow: Energy-Boosting Foods for Chronic Obstructive Pulmonary Disease
Category: Slideshows
Created: 6/18/2010 12:20:00 PM
Last Editorial Review: 11/20/2013 12:00:00 AM

COPD (Chronic Obstructive Pulmonary Disease) Quiz
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2012.11.06]
Title: COPD (Chronic Obstructive Pulmonary Disease) Quiz
Category: MedicineNet Quiz
Created: 10/8/2012 5:18:00 PM
Last Editorial Review: 11/6/2012 5:24:02 PM

Physical activity associated with lower rates of
 hospital readmission in patients with pulmonary disease
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2014.04.10]
Patients with chronic obstructive pulmonary disease (COPD) who participated in any level of moderate to vigorous physical activity had a lower risk of hospital readmission within 30 days compared...

COPD Drugs Need No Extra CV Study, Group Says
Source: MedPage Today Allergy & Immunology [2014.03.25]
(MedPage Today) -- Don't take drugs for chronic obstructive pulmonary disease (COPD) down the same path as those for diabetes by requiring cardiovascular outcome safety trials, a think tank panel told the FDA.

more news >>

Published Studies Related to Combivent (Ipratropium / Albuterol)

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. [2010.08]
We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study...

Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. [2009.12]
BACKGROUND: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination... CONCLUSION: Patients previously maintained on the ipratropium/albuterol combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours and superior bronchodilation during early morning hours.

Beneficial effects of warmed humidified oxygen combined with nebulized albuterol and ipratropium in pediatric patients with acute exacerbation of asthma in winter months. [2009.11]
BACKGROUND: The objective of this study was to determine whether a combination of nebulized albuterol and ipratropium with warmed humidified oxygen would be more beneficial when compared to the same combination with humidified oxygen at room temperature. Albuterol alone was tested in the same settings... CONCLUSION: Our study shows that warmed humidified oxygen given along with the combination of nebulized albuterol and ipratropium is more beneficial for pediatric patients having an acute exacerbation of bronchial asthma in the winter months when compared to nebulized albuterol alone with warmed humidified oxygen, nebulized albuterol alone with room temperature humidified oxygen, or a combination of nebulized albuterol and ipratropium with room temperature humidified oxygen.

The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. [2005.05]
BACKGROUND: The pathology of chronic obstructive pulmonary disease (COPD) includes both obstructive and inflammatory components. OBJECTIVE: The aim of this study was to confirm the findings of a previous study that compared the efficacy of a combination of 2 short-acting bronchodilators with the use of an inhaled corticosteroid and a long-acting beta-agonist in the treatment of COPD... CONCLUSION: In this 8-week study, subjects with moderate to severe COPD experienced greater improvements in lung function and symptom measures with FSC than with IB/ALB.

Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. [1997.08]
BACKGROUND: Routine addition of ipratropium bromide to beta-agonist therapy in acute asthma is of uncertain benefit. OBJECTIVE: This study was carried out to evaluate: (1) whether nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent) confers additional bronchodilation over nebulized salbutamol (2.5 mg) alone in patients with acute asthma and (2) whether adjustment for prognostic indicators of outcome influences any benefit seen with ipratropium... CONCLUSION: A single dose of nebulized Combivent confers additional bronchodilation over salbutamol alone (p < 0.05) in acute asthma. Patients who exhibited most benefit from the addition of ipratropium were those who had consumed the least inhaled beta-agonist before presentation, not those with the most severe asthma.

more studies >>

Clinical Trials Related to Combivent (Ipratropium / Albuterol)

Respimat Combivent Trial in COPD [Completed]
The primary objective of this study is to compare the effect of ipratropium bromide/salbutamol inhalation spray combination administered by the Respimat? inhaler (20 mcg/100 mcg), ipratropium bromide inhalation spray administered by the Respimat? inhaler (20 mcg), and COMBIVENT? MDI administered q. i.d on FEV1 at intervals over a treatment period of 12 weeks in patients with COPD. Specifically, non-inferiority of Combivent Respimat? to COMBIVENT? MDI in FEV1 AUC from 0 to 6 hours , superiority of Combivent Respimat? to Atrovent Respimat? monotherapy in FEV1 AUC from 0 to 4 hours, and non-inferiority of Combivent Respimat? to Atrovent Respimat? monotherapy in FEV1 AUC from 4 to 6 hours will b e analyzed. In addition, steady state pharmacokinetics over one dosing interval following 4 weeks of therapy will be characterized in a subgroup of patients.

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma [Recruiting]
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma. In the first cross-over part of the study (Treatment Phases 1 and 2) the marketed product, COMBIVENT CFC MDI will be used. In the second, parallel group part of the trial (Treatment Phase 3) COMBIVENT RESPIMAT will be tested for acute bronchodilator efficacy in a blinded manner at the clinic visits. During the third 4-week treatment phase open label COMBIVENT RESPIMAT will be used for symptom relief as needed.

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma [Completed]

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent? MDI.

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent? Inhalation Aerosol in COPD Patients. [Completed]
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler? 18 mcg daily compared to Combivent? MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent? MDI.

more trials >>

Reports of Suspected Combivent (Ipratropium / Albuterol) Side Effects

Drug Ineffective (64)Dyspnoea (61)Cough (29)Pneumonia (22)Drug Effect Decreased (16)Bronchitis (12)Asthma (11)Chronic Obstructive Pulmonary Disease (11)Throat Irritation (10)DRY Mouth (9)more >>


Page last updated: 2014-04-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012